Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Apellis Pharmaceuticals (APLS) Long-Term Debt Issuances (2020)

Apellis Pharmaceuticals filings provide 1 years of Long-Term Debt Issuances readings, the most recent being -$200000.0 for Q3 2020.